Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | GLA | P06280 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | NOS1 | P29475 | 9/20 | 0.68 |
| ▸ | NOS3 | P29474 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | DDAH1 | O94760 | 7/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL30577923 | 0.84 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30631154 | 0.84 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30679324 | 0.84 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288835 | 0.84 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288993 | 0.84 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL43261 | 0.84 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL31547986 | 0.82 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL29361849 | 0.82 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30074239 | 0.82 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL1532506 | 0.81 | NOS2 (0.92) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-08-14 | — | — | US | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| EP-4277592-A1 | TOPICAL COMPOSITION | Liliger Ltd (IL) | 2023-11-22 | — | — | EP | claimed |
| CN-116685302-A | Topical compositions | 利勒格有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | claimed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | claimed |
| US-10556005-B2 | Adjuvant composition containing citrulline | THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP) | 2020-02-11 | — | — | US | claimed |
| WO-2001074351-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT, IN NEWBORN BABIES, OF THE EFFECTS OF COMPLICATIONS DURING CHILDBIRTH | UNIVERSITAIR MEDISCH CENTRUM (NL) | 2001-10-11 | — | — | WO | claimed |
| WO-2000048591-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING ANGIOGENESIS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-08-24 | — | — | WO | claimed |
| US-5723448-A | Preventing conversion of citrulline to argininosuccinate to limit pathological nitric oxide overproduction | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION (US) | 1998-03-03 | — | — | US | claimed |
| EP-0707577-A4 | HEME BINDING COMPOUNDS AND USE THEREOF | WISCONSIN MED COLLEGE INC (US) | 1996-11-06 | — | — | EP | claimed |
| US-5545625-A | Preventing conversion of citrulline to argininosuccinate to limit pathological nitric oxide overproduction | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1996-08-13 | — | — | US | claimed |
| WO-1996018405-A1 | PREVENTING CONVERSION OF CITRULLINE TO ARGININOSUCCINATE TO LIMIT PATHOLOGICAL NITRIC OXIDE OVERPRODUCTION | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0707577-A1 | HEME BINDING COMPOUNDS AND USE THEREOF | MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1996-04-24 | — | — | EP | claimed |
| US-5464858-A | Heme binding compounds and use thereof | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1995-11-07 | — | — | US | claimed |
| US-5424447-A | Heme binding compounds and use thereof | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1995-06-13 | — | — | US | claimed |
| WO-1995001972-A1 | HEME BINDING COMPOUNDS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1995-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | NOS2 17/4885CYP2C19 2160/4885CYP1A2 910/4885 |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, PYGB | NOS2 13/4885CYP2C19 2098/4885CYP1A2 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.